Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2020
>
Lilly's solanezumab flunks latest Alzheimer's study; shares down 4% premarket
Lilly's solanezumab flunks latest Alzheimer's study; shares down 4% premarket
Read also
Biogen boosts rare disease pipeline with $5.6bn Apellis buyout deal
Biogen agreed to acquire Apellis for $5.6 billion, adding Syfovre and Empaveli and strengthening its rare disease and immunology pipeline.
FDA approves Lilly’s Foundayo GLP-1 weight loss pill with fewer rules
Eli Lilly’s Foundayo won FDA approval as a GLP-1 weight loss pill that can be taken without food and water restrictions, expanding obesity treatment options.
Rare disease advocates urge Trump team to restore FDA clarity now
A rare disease coalition urged the Trump administration to restore FDA clarity as leadership changes loom at the biologics review center.
FDA grants RMAT to allogeneic CAR T therapy for R/R multiple myeloma
FDA granted RMAT designation to CB-011 for relapsed or refractory multiple myeloma, supporting faster development and potential accelerated approval.
